Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis
To the Editor: Recently, many novel advanced systemic therapies have been approved for the treatment of moderate-to-severe atopic dermatitis (AD), including interleukin (IL)-4/IL-13 inhibitors (dupilumab), IL-13 inhibitors (tralokinumab), and selective Janus kinase (JAK)-1 inhibitors (abrocitinib and upadacitinib). There is uncertainty regarding the potential elevation of creatine phosphokinase (CPK) levels with these therapies, and whether this increase is linked to clinically significant outcomes, such as rhabdomyolysis and renal failure.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Daud Manzar, Emmanuel Suntres, Nikhil Nair, Yash Patel, Mohannad Abu-Hilal Tags: Research letter Source Type: research